262 related articles for article (PubMed ID: 29095108)
1. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.
Kulakova O; Bashinskaya V; Kiselev I; Baulina N; Tsareva E; Nikolaev R; Kozin M; Shchur S; Favorov A; Boyko A; Favorova O
Pharmacogenomics; 2017 Nov; 18(17):1563-1574. PubMed ID: 29095108
[TBL] [Abstract][Full Text] [Related]
2. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.
Ross CJ; Towfic F; Shankar J; Laifenfeld D; Thoma M; Davis M; Weiner B; Kusko R; Zeskind B; Knappertz V; Grossman I; Hayden MR
Genome Med; 2017 May; 9(1):50. PubMed ID: 28569182
[TBL] [Abstract][Full Text] [Related]
3. GWAS-identified multiple sclerosis risk loci involved in immune response: validation in Russians.
Bashinskaya VV; Kulakova OG; Kiselev IS; Baulina NM; Favorov AV; Boyko AN; Tsareva EY; Favorova OO
J Neuroimmunol; 2015 May; 282():85-91. PubMed ID: 25903733
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
Mahurkar S; Suppiah V; O'Doherty C
Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
[TBL] [Abstract][Full Text] [Related]
5. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Tsareva EY; Kulakova OG; Boyko AN; Shchur SG; Lvovs D; Favorov AV; Gusev EI; Vandenbroeck K; Favorova OO
Pharmacogenomics; 2012 Jan; 13(1):43-53. PubMed ID: 22111603
[TBL] [Abstract][Full Text] [Related]
6. The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
McKay FC; Gatt PN; Fewings N; Parnell GP; Schibeci SD; Basuki MA; Powell JE; Goldinger A; Fabis-Pedrini MJ; Kermode AG; Burke T; Vucic S; Stewart GJ; Booth DR
Clin Immunol; 2016 Feb; 163():96-107. PubMed ID: 26762769
[TBL] [Abstract][Full Text] [Related]
7. [Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis].
Tsareva EY; Favorova OO; Boyko AN; Kulakova OG
Mol Biol (Mosk); 2019; 53(4):574-599. PubMed ID: 31397433
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.
Grossman I; Avidan N; Singer C; Goldstaub D; Hayardeny L; Eyal E; Ben-Asher E; Paperna T; Pe'er I; Lancet D; Beckmann JS; Miller A
Pharmacogenet Genomics; 2007 Aug; 17(8):657-66. PubMed ID: 17622942
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
Kulakova OG; Tsareva EY; Lvovs D; Favorov AV; Boyko AN; Favorova OO
Pharmacogenomics; 2014 Apr; 15(5):679-85. PubMed ID: 24798724
[TBL] [Abstract][Full Text] [Related]
10. Mitonuclear interactions influence multiple sclerosis risk.
Kozin M; Kulakova O; Kiselev I; Baulina N; Boyko A; Favorova O
Gene; 2020 Oct; 758():144962. PubMed ID: 32687946
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].
Tsareva EIu; Kulakova OG; Makarycheva OIu; Boĭko AN; Shchur SG; Lashch NIu; Popova NF; Gusev EI; Bashinskaia VV; L'vov DV; Favorov AV; Ochs MF; Favorova OO
Mol Biol (Mosk); 2011; 45(6):963-72. PubMed ID: 22295566
[TBL] [Abstract][Full Text] [Related]
12. Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients.
Zarzuelo-Romero MJ; Pérez-Ramírez C; Cura Y; Carrasco-Campos MI; Marangoni-Iglecias LM; Ramírez-Tortosa MC; Jiménez-Morales A
J Pers Med; 2021 Oct; 11(10):. PubMed ID: 34683173
[TBL] [Abstract][Full Text] [Related]
13. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
[TBL] [Abstract][Full Text] [Related]
14. Variant of
Chen S; Zhang J; Liu QB; Zhuang JC; Wu L; Xu YF; Li HF; Wu ZY; Xiao BG
Chin Med J (Engl); 2018 Mar; 131(6):643-647. PubMed ID: 29521285
[TBL] [Abstract][Full Text] [Related]
15. A survey of endogenous retrovirus (ERV) sequences in the vicinity of multiple sclerosis (MS)-associated single nucleotide polymorphisms (SNPs).
Brütting C; Emmer A; Kornhuber M; Staege MS
Mol Biol Rep; 2016 Aug; 43(8):827-36. PubMed ID: 27169423
[TBL] [Abstract][Full Text] [Related]
16. ANKRD55 and DHCR7 are novel multiple sclerosis risk loci.
Alloza I; Otaegui D; de Lapuente AL; Antigüedad A; Varadé J; Núñez C; Arroyo R; Urcelay E; Fernandez O; Leyva L; Fedetz M; Izquierdo G; Lucas M; Oliver-Martos B; Alcina A; Saiz A; Blanco Y; Comabella M; Montalban X; Olascoaga J; Matesanz F; Vandenbroeck K
Genes Immun; 2012 Apr; 13(3):253-7. PubMed ID: 22130326
[TBL] [Abstract][Full Text] [Related]
17. Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis.
Hoppenbrouwers IA; Aulchenko YS; Janssens AC; Ramagopalan SV; Broer L; Kayser M; Ebers GC; Oostra BA; van Duijn CM; Hintzen RQ
J Hum Genet; 2009 Nov; 54(11):676-80. PubMed ID: 19834503
[TBL] [Abstract][Full Text] [Related]
18. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain.
Swaminathan B; Matesanz F; Cavanillas ML; Alloza I; Otaegui D; Olascoaga J; Cénit MC; de las Heras V; Barcina MG; Arroyo R; Alcina A; Fernandez O; Antigüedad A; Urcelay E; Vandenbroeck K
J Neuroimmunol; 2010 Jun; 223(1-2):100-3. PubMed ID: 20430450
[TBL] [Abstract][Full Text] [Related]
19. Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.
Dankowski T; Buck D; Andlauer TF; Antony G; Bayas A; Bechmann L; Berthele A; Bettecken T; Chan A; Franke A; Gold R; Graetz C; Haas J; Hecker M; Herms S; Infante-Duarte C; Jöckel KH; Kieseier BC; Knier B; Knop M; Kümpfel T; Lichtner P; Lieb W; Lill CM; Limmroth V; Linker RA; Loleit V; Meuth SG; Moebus S; Müller-Myhsok B; Nischwitz S; Nöthen MM; Paul F; Pütz M; Ruck T; Salmen A; Stangel M; Stellmann JP; Strauch K; Stürner KH; Tackenberg B; Then Bergh F; Tumani H; Waldenberger M; Weber F; Wiendl H; Wildemann B; Zettl UK; Ziemann U; Zipp F; Hemmer B; Ziegler A;
Genet Epidemiol; 2015 Dec; 39(8):601-8. PubMed ID: 26497834
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Patsopoulos NA; ; ; ; ; ; Esposito F; Reischl J; Lehr S; Bauer D; Heubach J; Sandbrink R; Pohl C; Edan G; Kappos L; Miller D; Montalbán J; Polman CH; Freedman MS; Hartung HP; Arnason BG; Comi G; Cook S; Filippi M; Goodin DS; Jeffery D; O'Connor P; Ebers GC; Langdon D; Reder AT; Traboulsee A; Zipp F; Schimrigk S; Hillert J; Bahlo M; Booth DR; Broadley S; Brown MA; Browning BL; Browning SR; Butzkueven H; Carroll WM; Chapman C; Foote SJ; Griffiths L; Kermode AG; Kilpatrick TJ; Lechner-Scott J; Marriott M; Mason D; Moscato P; Heard RN; Pender MP; Perreau VM; Perera D; Rubio JP; Scott RJ; Slee M; Stankovich J; Stewart GJ; Taylor BV; Tubridy N; Willoughby E; Wiley J; Matthews P; Boneschi FM; Compston A; Haines J; Hauser SL; McCauley J; Ivinson A; Oksenberg JR; Pericak-Vance M; Sawcer SJ; De Jager PL; Hafler DA; de Bakker PI
Ann Neurol; 2011 Dec; 70(6):897-912. PubMed ID: 22190364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
